Latest / DDReg Knowledge Capsule / Global-to-Local Pharmacovigilance: Bridging Safety Gaps

Transcript

Global-to-Local Pharmacovigilance: Bridging Safety Gaps · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to the D.D. Reg Knowledge Capsule.
• 0:03
  Speaker 2: Thank you. It is great to be here.
• 0:04
  Speaker 1: You know, when you think about global pharmaceutical companies, you
• 0:08
  Speaker 1: probably picture these massive, perfectly synchronized machines.
• 0:13
  Speaker 2: Oh, absolutely.
• 0:14
  Speaker 1: Like headquarters in Switzerland or the U.S., just managing data
• 0:18
  Speaker 1: with absolute precision. But today we are taking a deep
• 0:23
  Speaker 1: dive into a comprehensive guide from D.D. Reg Pharma that
• 0:27
  Speaker 1: really completely shatters that illusion.
• 0:29
  Speaker 2: It really does. It is a reality that catches a
• 0:32
  Speaker 2: lot of organizations off guard.
• 0:34
  Speaker 1: Yeah, because we are looking at the critical disconnects in
• 0:37
  Speaker 1: global to local pharmacovigilance governance, which is just a very
• 0:42
  Speaker 1: long way of saying how these highly advanced drug safety
• 0:45
  Speaker 1: systems can entirely break down the second they cross a border. Exactly.
• 0:49
  Speaker 2: And we have to approach this not just as a,
• 0:52
  Speaker 2: you know, a box ticking exercise in regulatory compliance. Right.
• 0:56
  Speaker 2: It is the fundamental architecture of patient safety. We are
• 1:00
  Speaker 2: talking about ensuring the seamless flow of life-saving data across
• 1:04
  Speaker 2: geographical boundaries.
• 1:05
  Speaker 1: And across time zones, right?
• 1:07
  Speaker 2: Time zones, entirely different corporate cultures, language barriers, you name it.
• 1:11
  Speaker 1: And that is the mission of this deep dive. We
• 1:14
  Speaker 1: are going to uncover exactly why a safety system that
• 1:17
  Speaker 1: looks absolutely flawless at global headquarters can still develop these massive,
• 1:23
  Speaker 1: dangerous blind spots at the local country level.
• 1:25
  Speaker 2: Because they absolutely do.
• 1:27
  Speaker 1: And more importantly... We're going to look at how MAHs,
• 1:30
  Speaker 1: marketing authorization holders, can actually fix these gaps.
• 1:34
  Speaker 2: Which is the crucial part.
• 1:35
  Speaker 1: So whether you are a compliance officer, someone working in
• 1:38
  Speaker 1: the life sciences, or honestly, if you are just navigating
• 1:42
  Speaker 1: any complex global organization, this deep dive is going to
• 1:45
  Speaker 1: show you how to prevent critical information from falling into
• 1:48
  Speaker 1: that Terrifying corporate void between headquarters and local affiliates.
• 1:52
  Speaker 2: Because that corporate void, that is where the real danger lies.
• 1:57
  Speaker 2: Headquarters might maintain a state-of-the-art global safety database. They might
• 2:01
  Speaker 2: boast this massive library of perfectly written SOPs mapping out
• 2:05
  Speaker 2: exactly how drug safety should be monitored.
• 2:07
  Speaker 1: Right, on paper it looks great.
• 2:08
  Speaker 2: Exactly. Centralizing a system on paper does not inherently make
• 2:12
  Speaker 2: it secure in practice.
• 2:14
  Speaker 1: Okay, let's unpack this because it feels like a paradox.
• 2:18
  Speaker 1: You'd think central control equals total control.
• 2:21
  Speaker 2: You would think so, yeah.
• 2:22
  Speaker 1: But it's more like a corporate game of telephone. Or actually,
• 2:27
  Speaker 1: think of it like a massive global restaurant franchise.
• 2:29
  Speaker 2: Oh, I like that. Right.
• 2:31
  Speaker 1: Headquarters creates this flawless master recipe. They write down every
• 2:35
  Speaker 1: single step. But if they don't account for the fact
• 2:37
  Speaker 1: that the local affiliate in Brazil has to use completely
• 2:40
  Speaker 1: different local ingredients.
• 2:42
  Speaker 2: Or a different supply chain entirely.
• 2:43
  Speaker 1: Exactly. Exactly. Or that a distributor in the Middle East
• 2:46
  Speaker 1: is working with totally different ovens. The end product is
• 2:50
  Speaker 1: going to be a disaster.
• 2:51
  Speaker 2: If we connect this to the bigger picture, that franchise
• 2:53
  Speaker 2: analogy is a perfect mirror for pharmacovigilance.
• 2:57
  Speaker 1: How so?
• 2:58
  Speaker 2: Well, think about the European Union framework and the role
• 3:00
  Speaker 2: of the QPPV, the qualified person for pharmacovigilance. Right.
• 3:05
  Speaker 1: The person in charge.
• 3:07
  Speaker 2: By law, that person must have absolute authority and total
• 3:11
  Speaker 2: visibility over the entire safety system.
• 3:13
  Speaker 1: Total visibility. Yes.
• 3:15
  Speaker 2: But if a local affiliate in another region is, you know,
• 3:18
  Speaker 2: hoarding safety information or maybe just interpreting a threshold differently
• 3:23
  Speaker 2: and not escalating that data up the chain.
• 3:26
  Speaker 1: Then the QPPV doesn't see it. Exactly.
• 3:28
  Speaker 2: That QPPV is essentially flying blind. And flying blind is
• 3:32
  Speaker 2: a direct violation of the EMA's GVP guidelines.
• 3:36
  Speaker 1: But how does that actually manifest day to day? Because
• 3:39
  Speaker 1: I have to assume nobody is intentionally hiding adverse events
• 3:42
  Speaker 1: from the QPPV.
• 3:43
  Speaker 2: Oh no, rarely intentional.
• 3:45
  Speaker 1: It has to be a structural failure, right?
• 3:47
  Speaker 2: It is entirely structural. The DD Reg Guide points out
• 3:50
  Speaker 2: that problems usually arise right at the local level because
• 3:53
  Speaker 2: of how responsibilities are communicated, or rather, how they aren't.
• 3:57
  Speaker 1: What do you mean?
• 3:58
  Speaker 2: Often a global manual will just state that the local
• 4:01
  Speaker 2: affiliate is responsible for quote-unquote local PV.
• 4:04
  Speaker 1: But what does local PV actually entail in that context? Exactly.
• 4:08
  Speaker 1: Does it mean the affiliate just forward emails to a
• 4:10
  Speaker 1: global inbox? Or does it mean they need to actively
• 4:13
  Speaker 1: monitor their region's local medical journals for adverse events? Right.
• 4:17
  Speaker 1: That ambiguity seems like a massive liability.
• 4:19
  Speaker 2: That ambiguity is exactly what sets up the failure. So
• 4:23
  Speaker 2: that's the first gap. The second is when those vague
• 4:25
  Speaker 2: responsibilities clash with global SOPs that just ignore country-specific requirements.
• 4:31
  Speaker 1: Right, because you can't just apply a global rule everywhere.
• 4:34
  Speaker 2: You cannot establish a rigid global baseline and assume it
• 4:37
  Speaker 2: overrides local law. National authorities have different reporting timelines and
• 4:41
  Speaker 2: entirely different documentation expectations.
• 4:44
  Speaker 1: So what happens when the global SOP doesn't match the
• 4:47
  Speaker 1: local law?
• 4:48
  Speaker 2: If the global SOP doesn't integrate those local realities, the
• 4:51
  Speaker 2: local teams are forced to improvise outside the system to
• 4:54
  Speaker 2: stay compliant in their own country.
• 4:56
  Speaker 1: Oh, wow. And when they improvise, the data gets siloed.
• 4:59
  Speaker 2: Exactly. Which brings us to the third issue, a one-way
• 5:02
  Speaker 2: street of communication. Right.
• 5:04
  Speaker 1: I imagine this gets even worse when local teams are
• 5:07
  Speaker 1: dutifully pushing all these adverse event reports up to headquarters,
• 5:10
  Speaker 1: but it's like dropping pennies down a well.
• 5:13
  Speaker 2: Yes. Global never replies.
• 5:16
  Speaker 1: They never send back the resulting safety decisions.
• 5:19
  Speaker 2: Which is operationally dangerous. If a local team flags a
• 5:22
  Speaker 2: potential safety signal based on their regional data, but global
• 5:25
  Speaker 2: headquarters absorbs that data without ever communicating the subsequent benefit
• 5:29
  Speaker 2: risk analysis back down.
• 5:31
  Speaker 1: Then the local affiliate can't act on it. Right.
• 5:34
  Speaker 2: They can't take appropriate regulatory action in their own market.
• 5:37
  Speaker 2: Then for the fourth issue, you compound that friction by
• 5:40
  Speaker 2: inserting third-party vendor interfaces.
• 5:43
  Speaker 1: Oh, the vendors.
• 5:44
  Speaker 2: Every time you route data through a local distributor, a
• 5:46
  Speaker 2: contract research organization, or an external service provider, things get
• 5:50
  Speaker 2: lost in translation.
• 5:52
  Speaker 1: I can totally see how that happens. Like, a local
• 5:54
  Speaker 1: CRO might summarize a patient report to fit their specific
• 5:58
  Speaker 1: vendor portal's character limit.
• 5:59
  Speaker 2: Yes, character limits are a real problem. Right.
• 6:02
  Speaker 1: And in doing so, they strip out crucial comorbidity context
• 6:05
  Speaker 1: before sending it to global.
• 6:07
  Speaker 2: Exactly.
• 6:08
  Speaker 1: And the global team has no idea they are looking
• 6:10
  Speaker 1: at truncated data.
• 6:11
  Speaker 2: That happens constantly. And the fifth and final trap headquarters
• 6:14
  Speaker 2: falls into is measuring success by activity rather than outcomes.
• 6:18
  Speaker 1: Meaning they just look at checkboxes.
• 6:20
  Speaker 2: Basically. Global headquarters will celebrate the fact that 100% of
• 6:24
  Speaker 2: the local team clicked through the annual safety training PowerPoint.
• 6:28
  Speaker 1: But they aren't checking if the actual data is transferring
• 6:30
  Speaker 1: correctly across that CRO interface you just mentioned.
• 6:33
  Speaker 2: Precisely.
• 6:34
  Speaker 1: Yeah, celebrating a completed checklist doesn't mean patients are safer.
• 6:37
  Speaker 1: It just means the compliance dashboard is green.
• 6:40
  Speaker 2: Which is a dangerous false sense of security.
• 6:43
  Speaker 1: And this perfectly transitions us into the operational reality of
• 6:46
  Speaker 1: where this life-saving data actually vanishes. Because safety data doesn't
• 6:50
  Speaker 1: just neatly arrive formatted in XML from highly controlled clinical trials.
• 6:54
  Speaker 2: No, it is incredibly messy. We are talking about deep
• 6:58
  Speaker 2: hidden black holes of safety data. Take local literature, for instance.
• 7:03
  Speaker 2: Headquarters might run highly sophisticated global literature searches across major
• 7:07
  Speaker 2: scientific databases like PubMed or Embase. But those global algorithms
• 7:12
  Speaker 2: will completely miss a critical case study published in a
• 7:15
  Speaker 2: local language publication or an unindexed national scientific journal in
• 7:19
  Speaker 2: Japan or Mexico.
• 7:20
  Speaker 1: Oh, wow. So if the local team isn't explicitly tasked
• 7:24
  Speaker 1: with monitoring those unindexed local publications... And, you know, given
• 7:28
  Speaker 1: the budget to do so, that safety signal just evaporates.
• 7:31
  Speaker 2: It just vanishes.
• 7:32
  Speaker 1: Another black hole the source material highlights is regulatory correspondence silos.
• 7:37
  Speaker 2: This one is huge. Right.
• 7:39
  Speaker 1: Imagine a national authority sends a labeling request to the
• 7:42
  Speaker 1: local regulatory affairs team.
• 7:44
  Speaker 2: The regulatory team usually views that strict correspondence as a
• 7:47
  Speaker 2: routine compliance task.
• 7:49
  Speaker 1: Just paperwork. Right.
• 7:50
  Speaker 2: They handle the paperwork, file the submission, and completely fail
• 7:53
  Speaker 2: to pass the underlying safety concern over to the local
• 7:56
  Speaker 2: pharmacovigilance team.
• 7:57
  Speaker 1: Because they just think it's a labeling issue.
• 7:58
  Speaker 2: Exactly. They don't realize that a minor labeling tweak requested
• 8:02
  Speaker 2: by a local health authority might be the first indicator
• 8:05
  Speaker 2: of a broader safety signal that the global PV team
• 8:08
  Speaker 2: needs to investigate.
• 8:09
  Speaker 1: Okay, here's where it gets really interesting, at least to me.
• 8:12
  Speaker 1: The craziest black hole mentioned in the source material revolves
• 8:16
  Speaker 1: around product complaints.
• 8:18
  Speaker 2: Oh, the quality complaints.
• 8:19
  Speaker 1: Yeah. Think about a routine customer service call. Someone calls
• 8:23
  Speaker 1: in and says, the blister pack on my medication is defective.
• 8:26
  Speaker 1: It's broken.
• 8:26
  Speaker 2: Right.
• 8:27
  Speaker 1: Or they complain about the liquid medication tasting incredibly bitter.
• 8:31
  Speaker 1: That ticket gets routed straight to the quality department.
• 8:34
  Speaker 2: And quality investigates the batch for manufacturing defects or contamination.
• 8:38
  Speaker 1: Right. But buried inside that complaint, the patient might have
• 8:42
  Speaker 1: casually mentioned to the rep, yeah, the packaging was broken,
• 8:45
  Speaker 1: and when I took the pill anyway, I got this
• 8:47
  Speaker 1: terrible rash.
• 8:48
  Speaker 2: A clear adverse event.
• 8:50
  Speaker 1: Exactly. Or maybe the medication tasted bitter because the patient
• 8:53
  Speaker 1: was experiencing a rare neurological reaction that alters taste perception.
• 8:58
  Speaker 1: That happens. If the quality software and the PV software
• 9:01
  Speaker 1: aren't actively integrated, quality just replaces the defective box, closes
• 9:05
  Speaker 1: the ticket as no contamination found, and that critical adverse
• 9:09
  Speaker 1: event data is gone forever.
• 9:11
  Speaker 2: Lost in the silo.
• 9:13
  Speaker 1: So how do companies realistically police these internal silos and
• 9:17
  Speaker 1: when quality and PV are using completely different software systems
• 9:20
  Speaker 1: and tracking different metrics.
• 9:22
  Speaker 2: This raises an important question for you, the listener, to
• 9:24
  Speaker 2: consider about your own organization. Where are your blind spots?
• 9:28
  Speaker 1: Seriously, they're everywhere.
• 9:30
  Speaker 2: The way sophisticated MAHs police this is by rigorously mapping
• 9:35
  Speaker 2: organizational interfaces.
• 9:36
  Speaker 1: Mapping them out? Yes.
• 9:38
  Speaker 2: The PSMF, the Pharmacovigilance System Master File, explicitly requires companies
• 9:43
  Speaker 2: to have visibility into these local and third-party sources. You
• 9:47
  Speaker 2: cannot just rely on an assumption that the head of
• 9:50
  Speaker 2: quality will walk down the hall and talk to the
• 9:52
  Speaker 2: head of PV.
• 9:53
  Speaker 1: Right. Relying on water cooler chats doesn't work.
• 9:55
  Speaker 2: You have to map the exact interface.
• 9:58
  Speaker 1: Meaning you need a formal mechanism. When quality receives a complaint,
• 10:02
  Speaker 1: what is the exact trigger, the exact timeline, and the
• 10:05
  Speaker 1: specific data fields required for transferring potential safety information to PV?
• 10:10
  Speaker 2: Correct. And that interface mapping gets exponentially more complicated when
• 10:15
  Speaker 2: the data leaves the company entirely.
• 10:17
  Speaker 1: Because of vendors.
• 10:18
  Speaker 2: Right. Every single time data passes to a third party,
• 10:21
  Speaker 2: like a local commercial distributor or an external patient support program,
• 10:26
  Speaker 2: the risk of delay doesn't just add up, it multiplies.
• 10:29
  Speaker 1: So if organizational silos and third party vendors are causing
• 10:33
  Speaker 1: all these black holes, the natural corporate reaction is usually,
• 10:37
  Speaker 1: let's bring in the lawyers.
• 10:37
  Speaker 2: Oh, always. Right.
• 10:39
  Speaker 1: Let's just write a much stricter contract. We'll force our
• 10:42
  Speaker 1: partners to comply under threat of financial penalty. But the
• 10:46
  Speaker 1: DD rate guide actually debunks that completely.
• 10:48
  Speaker 2: It addresses what we can call the contract fallacy.
• 10:51
  Speaker 1: The contract fallacy? Yes.
• 10:54
  Speaker 2: SDEA's safety data exchange agreements and pharmacovigilance agreements are foundational.
• 10:59
  Speaker 2: You absolutely need them in place.
• 11:01
  Speaker 1: Of course.
• 11:02
  Speaker 2: But at the end of the day, a signature on
• 11:03
  Speaker 2: a document does not prove operational success.
• 11:06
  Speaker 1: It's just a piece of paper.
• 11:07
  Speaker 2: Exactly. You cannot govern a dynamic, fast-moving safety system purely
• 11:12
  Speaker 2: through breach of contract clauses. The contract is just the blueprint.
• 11:16
  Speaker 2: The actual building requires a constant two-way street of information.
• 11:20
  Speaker 1: The bidirectional flow. Yes. Let's look at the local to
• 11:24
  Speaker 1: global direction first. The guide stresses that local teams shouldn't
• 11:27
  Speaker 1: just act as passive data entry clerks waiting for headquarters
• 11:32
  Speaker 1: to run algorithms.
• 11:33
  Speaker 2: Right.
• 11:34
  Speaker 1: They shouldn't wait for a safety signal to become globally
• 11:37
  Speaker 1: statistically significant. They need to escalate observations based on their
• 11:42
  Speaker 1: specific on-the-ground knowledge.
• 11:43
  Speaker 2: Because that local context is the most valuable asset an
• 11:48
  Speaker 2: MAH has.
• 11:49
  Speaker 1: Absolutely.
• 11:50
  Speaker 2: A local affiliate understands their specific patient population. They understand
• 11:54
  Speaker 2: local off-label prescribing habits, which might differ wildly from how
• 11:58
  Speaker 2: the drug is utilized in the country where headquarters is located.
• 12:01
  Speaker 1: Oh, that makes sense.
• 12:03
  Speaker 2: An adverse event might seem like a statistical anomaly to
• 12:06
  Speaker 2: the global database, but the local team might recognize it
• 12:10
  Speaker 2: immediately as a budding trend linked to a very specific
• 12:13
  Speaker 2: regional medical practice.
• 12:15
  Speaker 1: But the street has to go both ways. The flow
• 12:17
  Speaker 1: of information can't just stop at HQ.
• 12:20
  Speaker 2: No, it cannot.
• 12:21
  Speaker 1: Global teams have to push their benefit-risk decisions back down
• 12:24
  Speaker 1: to the local teams. You can't just, you know, suck
• 12:27
  Speaker 1: up all the data, make a ruling in a boardroom
• 12:29
  Speaker 1: in Geneva, and then leave the people on the ground
• 12:31
  Speaker 1: in Argentina in the dark.
• 12:33
  Speaker 2: Because an implementation cycle is not just an email blast. Right.
• 12:36
  Speaker 2: Sending a global risk management plan to an affiliate does
• 12:40
  Speaker 2: not mean the risk is managed.
• 12:42
  Speaker 1: They actually have to do the work.
• 12:44
  Speaker 2: The local team has to receive that plan, adapt it
• 12:47
  Speaker 2: to their local regulations, potentially negotiate with their local health
• 12:51
  Speaker 2: authority to approve new educational materials for doctors, execute the distribution,
• 12:56
  Speaker 2: and then crucially send evidence of that completion back to headquarters.
• 13:00
  Speaker 1: So what does this all mean? It makes me think
• 13:02
  Speaker 1: of a well-functioning pharmacovigilance system as being like a human
• 13:06
  Speaker 1: nervous system.
• 13:07
  Speaker 2: That's a great way to put it.
• 13:08
  Speaker 1: Right. It's not just about the sensory nerves in your
• 13:11
  Speaker 1: hands sending a pain signal up the arm to the brain.
• 13:13
  Speaker 1: That's your local to global flow.
• 13:16
  Speaker 2: Right.
• 13:16
  Speaker 1: But that is only half the job. The brain then
• 13:19
  Speaker 1: has to process that pain and send an actionable signal
• 13:22
  Speaker 1: back down the motor nerves to the muscles to actually
• 13:25
  Speaker 1: pull the hand away from the fire.
• 13:26
  Speaker 2: Exactly. Exactly.
• 13:28
  Speaker 1: If the brain registers the pain but doesn't send the
• 13:30
  Speaker 1: signal back down, well, the hand just burns.
• 13:33
  Speaker 2: What's fascinating here is that unlike the human nervous system,
• 13:36
  Speaker 2: the global brain, in pharmacovigilance, cannot send the exact same
• 13:40
  Speaker 2: motor signal to every muscle.
• 13:42
  Speaker 1: Oh, true.
• 13:42
  Speaker 2: Global decisions simply do not translate into identical actions worldwide.
• 13:47
  Speaker 2: If a global safety committee decides a warning label needs updating,
• 13:50
  Speaker 2: one regulatory authority might demand an immediate emergency Dear Healthcare
• 13:54
  Speaker 2: Professional letter sent out tomorrow.
• 13:56
  Speaker 1: While another authority.
• 13:58
  Speaker 2: Another authority in a neighboring country might require a completely different,
• 14:02
  Speaker 2: much slower phased regulatory pathway. The local team has to
• 14:06
  Speaker 2: interpret that global safety directive through the highly specific lens
• 14:09
  Speaker 2: of local law.
• 14:10
  Speaker 1: Which brings us to the ultimate question. How do we
• 14:13
  Speaker 1: actually operationalize this? Right. We've established the problem. We've found
• 14:17
  Speaker 1: the black holes. And we know we need this bidirectional
• 14:20
  Speaker 1: nervous system. So how does an MAH actually build it?
• 14:24
  Speaker 2: Instead of just throwing more SOPs at the problem, the
• 14:27
  Speaker 2: source material focuses on building a cohesive governance framework based
• 14:31
  Speaker 2: on causality.
• 14:32
  Speaker 1: And it starts with defining the operating model, right? Which
• 14:35
  Speaker 1: is the first of the seven steps in their framework.
• 14:37
  Speaker 2: Yes. You have to categorize the activities before you can
• 14:40
  Speaker 2: manage them. What is centrally managed by global? What is
• 14:44
  Speaker 2: locally executed by the affiliate? What is a shared responsibility?
• 14:48
  Speaker 2: And what is entirely outsourced to a vendor?
• 14:50
  Speaker 1: Because if you don't know that.
• 14:52
  Speaker 2: Until that architecture is clear, everything else is just guesswork.
• 14:55
  Speaker 1: And once you know who is supposed to be doing what,
• 14:57
  Speaker 1: the second step, you have to map those hidden interfaces
• 15:00
  Speaker 1: we discussed earlier.
• 15:01
  Speaker 2: Exactly.
• 15:02
  Speaker 1: But mapping interfaces sounds great in a boardroom. How do
• 15:06
  Speaker 1: you actually enforce that when you are dealing with an
• 15:09
  Speaker 1: external third-party vendor who might be using a legacy IT
• 15:12
  Speaker 1: system that doesn't talk to your global database?
• 15:15
  Speaker 2: That is where step three comes in. You have to
• 15:17
  Speaker 2: establish explicit granular accountability.
• 15:19
  Speaker 1: The RASI matrix.
• 15:20
  Speaker 2: Yes. It's not enough to say the vendor handles data transfer.
• 15:25
  Speaker 2: You use a RASI matrix to define exactly who is responsible, accountable, consulted,
• 15:30
  Speaker 2: and informed for every single step of that transfer.
• 15:32
  Speaker 1: Because if everyone is responsible, nobody is. Right.
• 15:35
  Speaker 2: Because when responsibility is vaguely shared across a corporate boundary,
• 15:40
  Speaker 2: nobody actually owns the outcome and the data falls through
• 15:43
  Speaker 2: the cracks.
• 15:44
  Speaker 1: Makes sense.
• 15:45
  Speaker 2: Once the RACI is set, step four is to standardize
• 15:48
  Speaker 2: the information exchange. Right. You define the exact transfer timelines,
• 15:53
  Speaker 2: the required data fields, and the contingency plan for when
• 15:57
  Speaker 2: the vendor's IT system goes down.
• 15:59
  Speaker 1: So the infrastructure is built. Step five, you build the
• 16:03
  Speaker 1: bidirectional governance. So the signals can go up and the
• 16:07
  Speaker 1: instructions can come down. Yes. But headquarters still has to
• 16:11
  Speaker 1: verify that local implementation actually happened, which is step six. Again,
• 16:16
  Speaker 1: communication does not completion. Never. Headquarters must demand physical or
• 16:20
  Speaker 1: digital evidence that a safety decision was enacted locally. And
• 16:24
  Speaker 1: to do that, you have to hit step seven, measuring
• 16:27
  Speaker 1: the interface by shifting your metrics.
• 16:29
  Speaker 2: This is vital. You move away from measuring activity like
• 16:33
  Speaker 2: training completion rates and start measuring outcomes like the percentage
• 16:37
  Speaker 2: of country actions implemented by the strict regulatory deadline.
• 16:41
  Speaker 1: And all of this framework relies on one critical control mechanism, right? Reconciliation.
• 16:47
  Speaker 2: Yes. The guide emphasizes reconciliation as the absolute strongest tool
• 16:52
  Speaker 2: an MAH has to audit this entire global to local flow.
• 16:57
  Speaker 1: Okay. I have to play devil's advocate here for a second.
• 17:00
  Speaker 2: Go for it.
• 17:01
  Speaker 1: Reconciliation is basically taking the local affiliates' logs, which might
• 17:05
  Speaker 1: just be a complex Excel sheet managed by a local
• 17:08
  Speaker 1: partner in Vietnam, and comparing it line by line against
• 17:11
  Speaker 1: the massive global safety database in Switzerland... to find any
• 17:14
  Speaker 1: unmatched cases.
• 17:16
  Speaker 2: That's the idea, yes.
• 17:17
  Speaker 1: If I'm a local affiliate, won't all this rigid reconciliation
• 17:22
  Speaker 1: and KPI tracking just bog me down in endless paperwork?
• 17:26
  Speaker 1: How does a local team survive that administrative burden?
• 17:29
  Speaker 2: It's a very understandable concern, and it's why poor reconciliation
• 17:33
  Speaker 2: processes fail. But strong governance is risk-based governance.
• 17:38
  Speaker 1: Risk-based?
• 17:39
  Speaker 2: It shouldn't bog you down. Because not every single local
• 17:41
  Speaker 2: data point requires daily, rigid escalation to the global safety committee.
• 17:46
  Speaker 2: If you escalate everything with the same urgency, you drown
• 17:49
  Speaker 2: the system in noise and create massive alert fatigue.
• 17:52
  Speaker 1: So how do you filter the noise?
• 17:54
  Speaker 2: By establishing proper thresholds. Technologically and procedurally, you prioritize. Fatal
• 18:00
  Speaker 2: or serious unexpected adverse events might require immediate, daily reconciliation
• 18:05
  Speaker 2: between the local tracker and the global database.
• 18:07
  Speaker 1: But routine wins.
• 18:09
  Speaker 2: Routine, non-serious events might only be reconciled monthly. When reconciliation
• 18:14
  Speaker 2: is risk-based, it doesn't create busy work. It acts as
• 18:17
  Speaker 2: a highly tuned filter, making the truly significant safety signals
• 18:20
  Speaker 2: much easier to spot because you aren't sifting through a chaotic,
• 18:24
  Speaker 2: undocumented mess of minor discrepancies.
• 18:27
  Speaker 1: That makes perfect sense. It focuses the resources where the
• 18:30
  Speaker 1: risk to the patient is highest.
• 18:32
  Speaker 2: Exactly.
• 18:33
  Speaker 1: And this highly targeted approach ties perfectly into how training
• 18:36
  Speaker 1: should be conducted across these interfaces.
• 18:39
  Speaker 2: Training cannot just be emailing someone a 200-page global SOP
• 18:43
  Speaker 2: and asking for a read and understand signature.
• 18:46
  Speaker 1: Nobody reads those anyway.
• 18:47
  Speaker 2: It has to be strictly role-based.
• 18:49
  Speaker 1: Right. A sales representative out in the field does not
• 18:52
  Speaker 1: need to understand the complex algorithmic rules for global signal detection. No,
• 18:57
  Speaker 1: they don't. They just need to know how to spot
• 18:59
  Speaker 1: a potential adverse event during a casual lunch with a doctor.
• 19:02
  Speaker 1: And they need to know the exact email address or
• 19:04
  Speaker 1: portal to send that observation to.
• 19:06
  Speaker 2: Tailoring the training to the specific interface ensures that people
• 19:10
  Speaker 2: actually absorb the information they need to keep the data flowing.
• 19:13
  Speaker 1: Otherwise, they just ignore it.
• 19:14
  Speaker 2: When you force a commercial rep to wade through irrelevant
• 19:17
  Speaker 2: regulatory jargon, they tune out. And that's when they miss
• 19:20
  Speaker 2: the casual mention of a side effect that should have
• 19:22
  Speaker 2: been reported.
• 19:23
  Speaker 1: So to bring this all together, we've covered incredible ground today.
• 19:27
  Speaker 2: We really have.
• 19:28
  Speaker 1: We learned that the biggest threat to global drug safety
• 19:30
  Speaker 1: isn't the lack of central oversight. Headquarters usually has its
• 19:34
  Speaker 1: house in order. The real threat is the fragile, often
• 19:37
  Speaker 1: ignored interface between headquarters and local teams.
• 19:40
  Speaker 2: The corporate void.
• 19:42
  Speaker 1: Yes, the void. We identified the black holes where data
• 19:46
  Speaker 1: gets lost, unindexed local literature, siloed regulatory correlations. and routine
• 19:51
  Speaker 1: customer complaints masquerading as quality issues. Right. We completely debunked
• 19:56
  Speaker 1: the idea that you could just sign a strict SDEA
• 19:58
  Speaker 1: and assume the data will flow. And we outlined how
• 20:01
  Speaker 1: building a bidirectional system requires explicit accountability, risk-based reconciliation, and
• 20:06
  Speaker 1: role-based training to actually fix the problem.
• 20:09
  Speaker 2: And I would say that if there is one core
• 20:11
  Speaker 2: takeaway from all of this, it's a fundamental shift in
• 20:14
  Speaker 2: how we view control, right? The ultimate goal of pharmacovigilance
• 20:18
  Speaker 2: governance is not to centralize everything in a tower and
• 20:22
  Speaker 2: strip local teams of their autonomy.
• 20:24
  Speaker 1: Because that just creates more problems.
• 20:25
  Speaker 2: That actually creates more blind spots. True, effective governance connects
• 20:30
  Speaker 2: local expertise to global oversight. It honors the nuances of
• 20:34
  Speaker 2: local markets and local laws. all the while allowing the
• 20:37
  Speaker 2: MAH to maintain one coherent and global view of product
• 20:41
  Speaker 2: safety across all the different, incredibly diverse regulatory environments.
• 20:45
  Speaker 1: It's about building a system that is as smart locally
• 20:49
  Speaker 1: as it is globally. Exactly. But I want to leave
• 20:51
  Speaker 1: you with a final thought to mull over, something that
• 20:54
  Speaker 1: builds on everything we've discussed today.
• 20:56
  Speaker 2: Okay.
• 20:57
  Speaker 1: Think about the sheer volume of data moving back and
• 20:59
  Speaker 1: forth across these interfaces. We are talking about millions of
• 21:02
  Speaker 1: data points, complaints, and reports being translated and transferred daily.
• 21:07
  Speaker 2: It is massive.
• 21:08
  Speaker 1: As artificial intelligence and automation inevitably begin to take over
• 21:12
  Speaker 1: these local to global handoffs, we have to ask ourselves,
• 21:15
  Speaker 1: will AI finally bridge these dangerous communication gaps and seamlessly
• 21:20
  Speaker 1: connect quality to PV?
• 21:23
  Speaker 2: Or?
• 21:24
  Speaker 1: Or will it just speed up our mistakes, misinterpret local context?
• 21:28
  Speaker 1: and create entirely new algorithmic black holes in our safety data?
• 21:32
  Speaker 2: That is a critical question for the next era of pharmacovigilance.
• 21:36
  Speaker 1: Thank you so much for joining us in diving deep
• 21:39
  Speaker 1: into the DDReg Knowledge Capsule today. Remember, a flawless master
• 21:43
  Speaker 1: recipe doesn't mean much if you don't know what's cooking
• 21:46
  Speaker 1: in the local kitchens. Keep your interfaces mapped, keep your
• 21:49
  Speaker 1: data flowing both ways, and we'll see you next time.